IKNA RSI Chart
Last 7 days
-5.7%
Last 30 days
8.0%
Last 90 days
-34.5%
Trailing 12 Months
-65.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 17.5M | 19.2M | 14.0M | 9.2M |
2022 | 30.9M | 27.7M | 30.4M | 15.6M |
2021 | 9.4M | 9.9M | 10.8M | 31.0M |
2020 | 0 | 0 | 0 | 9.2M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Aug 04, 2023 | bonita david p | acquired | - | - | 153,121 | - |
Aug 04, 2023 | orbimed advisors llc | acquired | - | - | 153,121 | - |
Jun 24, 2022 | bonita david p | bought | -803,975 | 4.96281 | -162,000 | - |
Jun 24, 2022 | orbimed advisors llc | bought | -803,975 | 4.96281 | -162,000 | - |
Jun 23, 2022 | orbimed advisors llc | bought | -86,884 | 3.71 | -23,419 | - |
Jun 23, 2022 | bonita david p | bought | -86,884 | 3.71 | -23,419 | - |
Jun 22, 2022 | orbimed advisors llc | bought | -237,161 | 3.55 | -66,806 | - |
Jun 22, 2022 | bonita david p | bought | -237,161 | 3.55 | -66,806 | - |
Which funds bought or sold IKNA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 11, 2024 | VANGUARD GROUP INC | added | 12.7 | -2,854,470 | 3,003,950 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 120 | 350 | 92,964 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | added | 24.14 | -23,356 | 30,310 | -% |
Feb 26, 2024 | Virtu Financial LLC | added | 130 | 2,000 | 53,000 | -% |
Feb 15, 2024 | Legal & General Group Plc | unchanged | - | -4,826 | 4,029 | -% |
Feb 15, 2024 | BARCLAYS PLC | added | 18.45 | -411,000 | 483,000 | -% |
Feb 15, 2024 | Farther Finance Advisors, LLC | sold off | -100 | -217 | - | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | new | - | 43,482 | 43,482 | -% |
Feb 15, 2024 | Blue Owl Capital Holdings LP | new | - | 3,848,620 | 3,848,620 | 0.92% |
Feb 14, 2024 | ORBIMED ADVISORS LLC | added | 11.09 | -6,823,560 | 6,972,540 | 0.14% |
Unveiling Ikena Oncology, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Ikena Oncology, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
Ikena Oncology, Inc. News
Income Statement (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Revenue | -44.4% | 1.00 | 1.00 | 2.00 | 5.00 | 5.00 | 6.00 | 0.00 | 3.00 | 20.00 | 4.00 | 4.00 | 3.00 | 0.00 | 3.00 | 3.00 | 3.00 |
Operating Expenses | 9.1% | 23.00 | 21.00 | 20.00 | 21.00 | 21.00 | 24.00 | 21.00 | 20.00 | 17.00 | 18.00 | 16.00 | 13.00 | 26.00 | 9.00 | 8.00 | 10.00 |
S&GA Expenses | 37.4% | 8.00 | 6.00 | 5.00 | 5.00 | 5.00 | 5.00 | 6.00 | 6.00 | 5.00 | 5.00 | 5.00 | 3.00 | 3.00 | 2.00 | 2.00 | 3.00 |
R&D Expenses | -2.6% | 14.00 | 15.00 | 15.00 | 16.00 | 16.00 | 19.00 | 15.00 | 14.00 | 12.00 | 13.00 | 11.00 | 10.00 | 23.00 | 7.00 | 6.00 | 8.00 |
Net Income | -12.4% | -19.49 | -17.34 | -17.11 | -14.22 | -14.10 | -17.34 | -20.49 | -16.84 | 3.00 | -14.51 | -12.68 | -9.72 | -26.05 | -6.22 | -5.04 | -6.94 |
Net Income Margin | -65.4% | -7.44* | -4.50* | -3.27* | -3.77* | -4.40* | -1.71* | -1.77* | -1.33* | -1.10* | -5.81* | -5.51* | -4.98* | - | - | - | - |
Free Cashflow | -10.4% | -22.08 | -20.00 | -18.14 | -19.94 | -17.89 | -18.35 | -19.49 | -19.82 | -13.92 | -18.17 | -15.91 | -14.01 | - | - | - | - |
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -10.8% | 192 | 215 | 172 | 152 | 172 | 190 | 211 | 228 | 248 | 262 | 279 | 294 | 168 |
Current Assets | -11.0% | 179 | 201 | 161 | 141 | 160 | 178 | 199 | 216 | 237 | 252 | 269 | 283 | 166 |
Cash Equivalents | -0.1% | 121 | 121 | 71.00 | 29.00 | 60.00 | 67.00 | 48.00 | 47.00 | 233 | 246 | 264 | 281 | 163 |
Net PPE | -11.3% | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 |
Liabilities | -20.6% | 22.00 | 28.00 | 15.00 | 17.00 | 25.00 | 32.00 | 37.00 | 35.00 | 40.00 | 58.00 | 63.00 | 66.00 | 63.00 |
Current Liabilities | -26.3% | 14.00 | 19.00 | 12.00 | 14.00 | 22.00 | 25.00 | 29.00 | 25.00 | 27.00 | 31.00 | 31.00 | 30.00 | 28.00 |
Shareholder's Equity | 9.3% | 170 | 155 | 157 | 135 | 147 | 159 | 174 | 193 | 208 | 203 | 216 | 228 | - |
Retained Earnings | -7.4% | -282 | -262 | -245 | -228 | -214 | -200 | -182 | -162 | -145 | -148 | -133 | -121 | -111 |
Additional Paid-In Capital | 8.0% | 452 | 418 | 403 | 364 | 362 | 360 | 358 | 356 | 353 | 351 | 350 | 349 | 10.00 |
Shares Outstanding | 9.4% | 48.00 | 44.00 | 42.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 25.00 | 36.00 | 4.00 | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | -9.1% | -21,819 | -19,997 | -18,143 | -19,784 | -17,655 | -17,219 | -19,451 | -19,784 | -13,368 | -17,990 | -15,724 | -13,170 | -12,570 | -7,670 | -7,712 | -9,874 |
Share Based Compensation | -12.2% | 1,755 | 1,998 | 1,879 | 2,000 | 1,859 | 1,811 | 1,955 | 1,900 | 1,581 | 1,449 | 1,262 | 885 | 650 | 418 | 354 | 375 |
Cashflow From Investing | -36.1% | 20,376 | 31,894 | 22,680 | -10,806 | 10,499 | 35,782 | 20,486 | -166,051 | -550 | -184 | -187 | -839 | 3,038 | - | 1.00 | -117 |
Cashflow From Financing | -99.8% | 60.00 | 38,918 | - | - | 1.00 | 24.00 | 575 | 495 | 236 | 69.00 | -1,095 | 132,528 | 116,163 | - | - | 21.00 |
Buy Backs | - | - | - | 663 | - | - | - | - | - | - | - | - | - | - | - | - | - |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue | ||
Research and development revenue under collaboration agreement | $ 9,160 | $ 15,618 |
Revenue from Contract with Customer, Product and Service [Extensible List] | us-gaap:InProcessResearchAndDevelopmentMember | us-gaap:InProcessResearchAndDevelopmentMember |
Operating expenses | ||
Research and development | $ 59,652 | $ 64,321 |
General and administrative | 24,925 | 22,201 |
Total operating expenses | 84,577 | 86,522 |
Loss from operations | (75,417) | (70,904) |
Other income (expense) | ||
Investment income | 7,111 | 2,149 |
Other expense | (22) | (10) |
Total other income, net | 7,089 | 2,139 |
Loss before income taxes | (68,328) | (68,765) |
Income tax benefit (expense) | 162 | |
Net loss | (68,166) | (68,765) |
Other comprehensive loss: | ||
Unrealized loss on marketable securities | 715 | (763) |
Total comprehensive loss | $ (67,451) | $ (69,528) |
Net loss per share: | ||
Net loss per share attributable to common stockholders basic | $ (1.63) | $ (1.9) |
Net loss per share attributable to common stockholders diluted | $ (1.63) | $ (1.9) |
Weighted-average common shares outstanding, basic | 41,735,081 | 36,188,420 |
Weighted-average common shares outstanding, diluted | 41,735,081 | 36,188,420 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 119,894 | $ 59,919 |
Marketable securities | 55,571 | 97,028 |
Prepaid expenses and other current assets | 3,197 | 3,063 |
Total current assets | 178,662 | 160,010 |
Property and equipment, net | 2,335 | 3,205 |
Right-of-use asset | 5,686 | 5,255 |
Deposits and other assets | 5,409 | 3,789 |
Total assets | 192,092 | 172,259 |
Current liabilities: | ||
Accounts payable | 2,066 | 2,093 |
Accrued expenses and other current liabilities | 8,581 | 8,343 |
Operating lease liability | 3,558 | 1,907 |
Deferred revenue | 9,160 | |
Total current liabilities | 14,205 | 21,503 |
Long-term portion of operating lease liability | 7,180 | 3,787 |
Other long term liabilities | 950 | |
Total liabilities | 22,335 | 25,290 |
Commitments and contingencies (Note 15) | ||
Stockholders' equity: | ||
Preferred Stock, $0.001 par value, 10,000,000 shares authorized as of December 31,2023 and 2022; No shares issued and outstanding as of December 31, 2023 or December 31, 2022 | ||
Common stock, $0.001 par value, 150,000,000 shares authorized, 48,258,111 shares issued and outstanding as of December 31, 2023; 150,000,000 shares authorized, 36,257,493 shares issued and outstanding as of December 31, 2022 | 48 | 36 |
Additional paid-in capital | 452,142 | 361,915 |
Accumulated other comprehensive loss | (48) | (763) |
Accumulated deficit | (282,385) | (214,219) |
Total stockholders' equity | 169,757 | 146,969 |
Total liabilities and stockholders' equity | $ 192,092 | $ 172,259 |